Are we measuring what matters most on uptake to medicines in England?In the second of a two-part series, Leela Barham argues that whilst international comparisons of uptake are useful, Share XAre we measuring what matters most on uptake to medicines in England?https://pharmaphorum.com/market-access-2/measuring-uptake-medicines-england/
Getting better at measuring international uptake of medicines?In part one of a two-piece series, Leela Barham looks at whether we are getting better at measuring Share XGetting better at measuring international uptake of medicines?https://pharmaphorum.com/market-access-2/getting-better-at-measuring-international-uptake-of-medicines/
A test of NICE’s resolve: clinical guidelines for Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)The work of the UK’s HTA body, the National Institute for Health and Care Excellence (NICE), is often Share XA test of NICE’s resolve: clinical guidelines for Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)https://pharmaphorum.com/views-and-analysis/guidelines-myalgic-encephalomyelitis-chronic-fatigue-syndrome/
A problem combination?Leela Barham takes stock of past NICE decisions for combinations to explore the scale of the reimbursement challenge Share XA problem combination?https://pharmaphorum.com/views-and-analysis/a-problem-combination/
NICE feedback?The National Institute for Health and Care Excellence (NICE) is quite far along a NICE-led process to review Share XNICE feedback?https://pharmaphorum.com/views-and-analysis/nice-feedback/
What’s affordable anyway? The future of NHS drug spendingThe single biggest monetary difference that can be made to the successor to the UK’s 2019 Voluntary Scheme Share XWhat’s affordable anyway? The future of NHS drug spendinghttps://pharmaphorum.com/views-and-analysis/vpas-future-nhs-drug-spending/
2021 market access prospects for FranceIn the latest of a suite of features looking at the biggest markets in Europe, Leela Barham takes Share X2021 market access prospects for Francehttps://pharmaphorum.com/views-analysis-market-access/2021-market-access-prospects-for-france/
2021 market access prospects for Spain2021 will be the year when big market access changes – including the far wider use of health Share X2021 market access prospects for Spainhttps://pharmaphorum.com/views-analysis-market-access/2021-market-access-prospects-for-spain/
2021 market access prospects for GermanyThe market access landscape in Germany is particularly interesting in 2021, as a key component – AMNOG – Share X2021 market access prospects for Germanyhttps://pharmaphorum.com/views-analysis-market-access/2021-market-access-prospects-for-germany/
